Protara Therapeutics (TARA) Change in Account Payables (2019 - 2026)
Protara Therapeutics (TARA) posted quarterly Change in Account Payables of $1.1 million for Q1 2026, up 172.41% year-over-year from $399769.6 in Q1 2025, and up 169.72% quarter-over-quarter from -$1.6 million in Q4 2025.
Powered by 
Analysis
Protara Therapeutics (TARA) Change in Account Payables (2019 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Change in Account Payables for 8 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 172.41% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.7 million (up 28.45% YoY), while the FY2025 annual figure was -$873000.0, down 163.22% from the prior year.
- Change in Account Payables grew to $1.1 million in Q1 2026 per TARA's latest filing, from -$1.6 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $3.0 million in Q2 2025 and bottomed at -$2.2 million in Q2 2023.
- Historically, Change in Account Payables has averaged $180941.2 across 5 years, with a median of $64000.0 in 2022.
- Annual changes were most pronounced in 2022 — Change in Account Payables surged 4242.31% — and 2023, when it plunged 1395.97%.
- Protara Therapeutics' Change in Account Payables stood at $1.1 million in 2022, then tumbled by 106.2% to -$70000.0 in 2023, then jumped by 2271.43% to $1.5 million in 2024, then plunged by 202.76% to -$1.6 million in 2025, then jumped by 169.72% to $1.1 million in 2026.
- Business Quant data shows TARA's Change in Account Payables at $1.1 million in Q1 2026, -$1.6 million in Q4 2025, and -$795000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Protara Therapeutics | 241.28 Mn | 241.28 Mn | - | 243,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 243,000.00 |
| Mar 31, 2026 | 1.09 Mn |
| Dec 31, 2025 | -1.56 Mn |
| Sep 30, 2025 | -795,000.00 |
| Jun 30, 2025 | 2.99 Mn |
| Mar 31, 2025 | -1.50 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | 910,000.00 |
| Jun 30, 2024 | 413,000.00 |
| Mar 31, 2024 | -1.46 Mn |
| Dec 31, 2023 | -70,000.00 |
| Sep 30, 2023 | 652,000.00 |
| Jun 30, 2023 | -2.23 Mn |
| Mar 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 1.13 Mn |
| Sep 30, 2022 | 64,000.00 |
| Jun 30, 2022 | -149,000.00 |
| Mar 31, 2022 | -413,000.00 |
| Dec 31, 2021 | 26,000.00 |
| Sep 30, 2021 | -475,000.00 |